

## 510(k) Summary

MAY 29 2003

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92.

## 1. The submitter of this premarket notification is:

Hauke Schik

Philips Medizin Systeme Boeblingen GmbH

Hewlett-Packard-Str. 2

D-71034 Boeblingen, Germany

Tel: ++49 7031 463-2031 Fax: ++49 7031 463-2442

e-mail: [hauke.schik@philips.com](mailto:hauke.schik@philips.com)

This summary was prepared on May 05, 2003.

## 2. The names of the devices are the Philips MP60, MP70, and MP90 IntelliVue Patient Monitor. Classification names are as follows:

Device Panel	Classification	ProCode	Description
Circulatory System Devices (12625)	§870.1025, III	DSI	Detector and alarm, arrhythmia
	§870.1025, III	MLD	Monitor, ST Segment with Alarm
	§870.1025, III	MHX	Monotor, Physiological, Patient (with arrhythmia detection or alarms)
	§870.1100, II	DSJ	Alarm, Blood Pressure
	§870.1110, II	DSK	Computer, Blood Pressure
	§870.1130, II	DXN	System, Measurement, Blood-Pressure, Non-Invasive
	§870.1435, II	DXG	Computer, Diagnostic, Pre-Programmed, Single-Function
	§870.1915, II	KRB	Probe, Thermodilution
	§870.2060, II	DRQ	Amplifier and Signal Conditioner, Transducer Signal
	§870.2300, II	DRT	Monitor, Cardiac (incl. Cardiotachometer & Rate Alarm)
	§870.2340, II	DPS	Electrocardiograph
	§870.2340, II	MLC	Monitor, ST Segment
	§870.2350, II	DRW	Electrocardiograph, Lead Switching Adapter
	§870.2370, II	KRC	Tester, Electrode, Surface, Electrocardiograph
	§870.2450, II	DXJ	Display, Cathode-Ray Tube, Medical
	§870.2600, I	DRJ	System, Signal Isolation
	§870.2700, II	DQA	Oximeter
	§870.2770, II	DSB	Plethysmograph, Impedance
	§870.2800, II	DSH	Recorder, Magnetic tape, Medical
	§870.2810, I	DSF	Recorder, Paper Chart
	§870.2850, II	DRS	Extravascular Blood Pressure Transducer
	§870.2900, I	DSA	Cable, Transducer and Electrode, incl. Patient Connector

	-	MSX	System, Network and Communication, Physiological Monitors
Anesthesiology and Respiratory Therapy (12624)	\$868.1400, II	CCK	Analyzer, Gas, Carbon Dioxide, Gaseous-Phase
	\$868.1500, II	CBQ	Analyzer, Gas, Enflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1500, II	NHO	Analyzer, Gas, Desflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1500, II	NHP	Analyzer, Gas, Sevoflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1500, II	NHQ	Analyzer, Gas, Isoflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1620, II	CBS	Analyzer, Gas, Halothane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1700, II	CBR	Analyzer, Gas, Nitrous Oxide, Gaseous-Phase (Anesthetic Concentration)
	\$868.1720, II	CCL	Analyzer, Gas, Oxygen, Gaseous-Phase
	\$868.2375, II	BZQ	Monitor, Breathing Frequency
	\$868.2480, II	LKD	Monitor, Carbon Dioxide, Cutaneous
	\$868.2500, II	KLK	Monitor, Oxygen, Cutaneous, for Infant not under Gas Anesthesia
General Hospital and Personal Use (12520)	\$880.2910, II	FLL	Thermometer, Electronic, Clinical
Neurological (12513)	\$882.1400, II	GWR	Electroencephalograph
	\$882.1420, I	GWS	Analyzer, Spectrum, Electroencephalogram Signal

3. The new devices are substantially equivalent to previously cleared Philips devices marketed pursuant to K001664, K021778 and 030038.
4. The modification is updated software of the Philips Medical System MP60, MP70 and MP90 IntelliVue patient monitor devices.
5. The new devices have the same intended use as the legally marketed predicate devices. When used in the hospital environment, they are intended for the monitoring, recording, and alarming of multiple physiological parameters of adults, pediatrics, and neonates.
6. The new devices have the same technological characteristics as the legally marketed predicate devices.
7. Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the new device with respect to the

predicate. Testing involved system level tests, performance tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate device and test results showed substantial equivalence. The results demonstrate that Component Compact Monitor meets all reliability requirements and performance claims.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

**MAY 29 2003**

Philips Medizin Systeme Boeblingen GmbH  
c/o Mr. Hauke Schik  
Sr. Regulatory Affairs Engineer  
Cardiac and Monitoring Systems  
Hewlett-Packard Str. 2  
Boeblingen  
Germany D-71034

Re: K031481

Trade Name: The Philips MP60, MP70 and MP90 IntelliVue Patient Monitors  
Regulation Number: 21 CFR 870.1025  
Regulation Name: Arrhythmia detector and alarm  
Regulatory Class: Class III (three)  
Product Code: MHX  
Dated: May 5, 2003  
Received: May 12, 2003

Dear Mr. Schik:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 – Mr. Hauke Schik

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman", is written over the typed name and title.

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

510(k) Number (if known): K031481

Device Name: The Philips IntelliVue MP60, MP70, and MP90 Patient Monitors, Release A.20.

Indications for Use: Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring, recording and alarming of multiple physiological parameters of adults, pediatrics and neonates in hospital environments.

EASI 12-lead ECG is only for use on adult and pediatric patients.

ST Segment monitoring is restricted to adult patients only.

The transcutaneous gas measurement (tcpO<sub>2</sub> / tcpCO<sub>2</sub>) is restricted to neonatal patients only.

---

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)


Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒  
(Per 21 CFR 801.109)

OR

Over-The-Counter

(Optional Format 1-2-96)

  
(Division Sign-Off)  
Division of Cardiovascular Devices

510(k) Number K031481